Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3K/Akt-mTOR Pathway
The role of LY294002 on protective effect of SZL-medicated serum on STZ-injured OLN-93 cells. (a) Effect of LY294002 on SZL-medicated serum-increased cell viability of injured OLN-93 cells. Effect of LY294002 on SZL-medicated serum-induced up-regulation of p-Akt (b) and MBP (c, d) in injured OLN-93 cells; C, control group; M, model group; M + LY-294, model + LY294002 group; Don, donepezil group; Don + LY-294, donepezil + LY294002 group; SZL, SZL-medicated serum group; SZL + LY-294, SZL-medicated serum + LY294002 group. , significantly different from control group. and , significantly different from model group. , significantly different from donepezil group; , significantly different from SZL-medicated serum group. Each point represents the mean ± SD of n = 6 experiments.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.